Indian Society19 November 20264 min read
Health Ministry proposes tighter oversight of drug storage, bulk sales and approvals
The Union Ministry of Health and Family Welfare has proposed amendments to drug regulations covering medicine storage, bulk-drug sales, requirements for three product categories and antimicrobial approvals.
The proposals would add storage and distribution practices to the Drugs Rules, 1945, create separate wholesale licensing forms for bulk drugs, allow product-specific decisions on some Schedule M requirements and include antimicrobials in the definition of a new drug.
How proposed storage rules would cover the medicine supply chain
The proposal would incorporate Good Storage and Distribution Practices (GSDP) into the Drugs Rules, 1945, drawing on guidance developed by the Central Drugs Standard Control Organisation (CDSCO). The practices would apply from the manufacturer or importer to the patient and cover:
- Procurement and purchasing
- Storage, distribution and transportation
- Documentation and record-keeping
The proposed framework is intended to preserve product quality, safety, efficacy, identity and integrity. It addresses risks of deterioration, contamination, mix-ups, falsification, diversion and unauthorised distribution.
The Ministry expects the requirements to support inspection and enforcement by Central and State drug-control authorities. It also expects them to improve traceability and accountability among manufacturers, importers, wholesalers, distributors, stockists and other supply-chain entities. The draft Official Gazette notification is available here.
How the bulk-drug licensing proposal would change wholesale sales
Draft G.S.R. No. 987 (E), dated 2 November 2026, proposes separate application and licence forms, Form 19-BC and Form 20-BC, for the wholesale sale of bulk drugs, including active and inactive bulk substances. A common licence currently covers wholesale sales of both formulations and bulk drugs.
The proposed framework would identify the categories of bulk drugs handled, including those covered by the Narcotic Drugs and Psychotropic Substances Act, 1985. Sales would have to take place under the personal supervision of a competent person.
The Drugs Consultative Committee (DCC) agreed to the proposal at its 67th meeting on 17 November 2025. The Drugs Technical Advisory Board (DTAB) agreed to it at its 93rd meeting on 16 February 2026. The draft notification is available here.
Why some products may receive exemptions from revised Schedule M
Draft G.S.R. 985 (E), dated 6 November, concerns medicinal gases, empty gelatin capsules and disinfectant fluids. After stakeholder representations, the DTAB considered how revised Schedule M, notified through G.S.R. 922(E) on 28 December 2023, would apply to these products.
The Board observed that some requirements may not suit their manufacturing processes and recommended continuing exemptions that applied before the revision. The proposal would allow Licensing Authorities to make product-specific decisions on scientific and practical grounds, while retaining applicable quality standards and regulatory oversight. The draft notification is available here.
How the antimicrobial proposal would change manufacturing approvals
Draft G.S.R. 983 (E), dated 6 November, proposes amending the New Drugs and Clinical Trials Rules, 2019, to include ‘antimicrobials’ in the definition of ‘New Drug’ under Rule 2(1)(w)(v).
The proposal responds to concerns that manufacturing licences may be granted without adequate scrutiny, including bioavailability/bioequivalence and stability studies. Inadequate assessment could affect product quality, safety and efficacy. Substandard or ineffective antimicrobials can contribute to antimicrobial resistance (AMR) and threaten patient safety. AMR is a major global public-health concern, and the G20 New Delhi Leaders’ Declaration called for action through a One Health approach.
If adopted, manufacturers would need permission from the Central Licensing Authority and State Licensing Authority before applying to the concerned State Licensing Authority for a manufacturing licence. The draft notification is available here.
What stakeholders can submit and when the proposals may take effect
All four proposals remain at the consultation stage. Under the bulk-drug proposal, existing licensees would have until the end of their current retention period or 12 months after final publication, whichever is later, to comply.